Skip to main content
. 2023 Oct 2;14:1267749. doi: 10.3389/fimmu.2023.1267749

Table 5.

Observed and expected numbers of malignancies and their SIR with 95% CI.

O/E SIR 95% CI p-Value
JAKi 12/5.71 2.10 1.23–2.97 0.02*
IL-6i 10/9.21 1.09 0.56–1.61 0.76

IL-6i, interleukin-6 receptor inhibitors; JAKi, Janus kinase inhibitors; CI, confidence interval; E, expected number; O, observed number; SIR, standardized incidence ratio.